热原测试的全球市场：市场规模和份额分析（按产品、类型、最终用户） - 工业需求预测（截至 2030 年）

2023 年，全球热原测试市场收入达到 14.064 亿美元，预计 2024 年至 2030 年复合年增长率为 7.3%，达到 22.842 亿美元。 该市场的成长归因于生物製药领域对热原测试的接受度不断提高。

此外，生物技术和製药行业的不断发展，以及新生物製剂研究和行销的增加，预计将推动对这些测试的需求，以生产更安全、更好的药物。

热原测试是使每种药物和治疗剂更安全、更有效的重要一步。 癌症病例和遗传性疾病数量的迅速增加导致了治疗方法的改进，在这些疾病的治疗中取得了成效。

个人化医疗的优点在于利用人们的基因图谱来帮助做出有关疾病预防、诊断和治疗的决策。 因此，患者和公司正在迅速接受改进的药物。 此外，基于临床和基因组特征的改良治疗在癌症和免疫疾病患者中越来越受欢迎。 因此，改良药物的需求不断增加是推动热原测试解决方案需求的主要原因之一。

从最终用户来看，製药和生物技术公司将在 2023 年占据收入的最大份额，达到 35%，并且这一趋势预计将持续下去。 这是由药品、生物製品和新药产量的增加以及热原测试需求的增加所推动的。 此外，该类别的市场成长是由于对个人化医疗的日益偏好、传染病和慢性病盛行率的增加而推动的。

北美地区2023年销售量增幅最高，市占率最高为55%。 这是由于生物技术和製药的持续成长。我们使用 cookie 来改善您的体验。 促进该地区市场成长的其他关键因素包括扩大处方药管道、增加药品审批以及提高产品安全和食品安全意识。

在北美地区，美国在该产业占据主导地位。 其主要原因是先进的医疗基础设施、对新药开发的关注以及辉瑞和罗氏等主要生物技术和生物製药公司的存在。

此外，加拿大对北美工业也有显着的好处。 这是由于该国製药和生物技术行业的崛起、药品安全意识的增强以及研发活动的增加。

本报告分析了全球热原测试市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、按地区和主要国家的市场规模前景（以货币形式计算） ，（2017-2030 ），按类型、用途、动物和最终用户划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/挑战
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
  • 外科手术市场收入：按类型划分（2017-2030 年）
• 市场收入：以动物分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：按地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
  • 外科手术市场收入：按类型划分（2017-2030 年）
• 市场收入：以动物分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

• 摘要
• 市场收入：依类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
  • 外科手术市场收入：按类型划分（2017-2030 年）
• 市场收入：以动物分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Charles River Laboratories International Inc.
• Merck KGaA
• Thermo Fisher Scientific Inc.
• FUJIFILM Wako Pure Chemical Corporation
• WuXi AppTec Co. Ltd.
• Microcoat Biotechnologie GmbH
• Nelson Laboratories LLC
• Lonza Group Ltd.
• Ellab A/S
• GenScript Biotech Corporation

第31章附录

Revenue of USD 1,406.4 million was generated in the global Pyrogen Test Market for 2023, which is expected to grow at a compound annual growth rate of 7.3% over the period from 2024 to 2030 and reach USD 2,284.2 million. This growth of the market can be credited to the increasing acceptance of pyrogen testing within the biopharmaceutical sector.

Furthermore, the rising development in the biotechnology and pharmaceutical industries along with the increasing count of new biologics research and introductions is projected to fuel the demand for these testing for making safe and better drugs.

Pyrogen testing is a vital step for each medication and therapeutics to make it safer and more effective. Surge in the count of cancer cases and hereditary illnesses, modified treatments attained benefits in the treatment of these diseases.

Tailored medicine has the benefit that it uses people's hereditary profiles to aid in decision-making for the prevention, diagnosis, and treatment of illnesses. Therefore, patients and businesses are quickly accepting modified drugs. Furthermore, modified treatment-based methods to clinical and genomic features are becoming more popular among patients with cancer and immunologic sicknesses. Hence, the increasing need for modified drugs is one of the key reasons propelling the demand for pyrogen testing solutions.

On the basis of the end user, the category of pharmaceutical and biotechnology companies accounted for the largest revenue share of 35% in 2023 and is expected to remain so in the future. This has been driven by the increase in the manufacturing of medicines, biologics, and new drugs as well as a growing demand for pyrogen testing. In addition, the market growth in this category is being driven by a growing preference for personalized medicine as well as an increasing incidence of infectious and chronic diseases.

The foremost sales generator in 2023, North America accounted for the highest market percentage of 55%. That is due to the continuing growths in biotechnology and pharmaceutical wherein cookies are used to make your experience better. Other key factors that have contributed to the increase of the local marketplace consist of an extended pipeline of prescribed drugs, an upward thrust in drug approvals as well as growing awareness about product safety and food security.

In the North American region, the U.S. dominates the industry. This is mainly because of the existence of advanced healthcare infrastructure, augmented concentration on new drug growth, and the presence of key biotechnology and biopharmaceutical companies, like Pfizer Inc. and F. Hoffmann-La Roche AG, in the country.

Furthermore, Canada is also generating substantial revenue for the North American industry. This can be credited to the rising pharmaceutical and biotechnology sector, the rising awareness regarding the safety of medications, and the growing R&D activities in the country.

Top Providers of Pyrogen Testing Are:

Charles River Laboratories International Inc.

Merck KGaA

Thermo Fisher Scientific Inc.

FUJIFILM Wako Pure Chemical Corporation

WuXi AppTec Co. Ltd.

Microcoat Biotechnologie GmbH

Nelson Laboratories LLC

Lonza Group Ltd.

Ellab A/S

GenScript Biotech Corporation

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by animal
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Type (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
  • 6.3.1. Surgery market revenue, by type (2017-2030)
• 6.4. Market Revenue, by Animal (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Type (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
  • 7.3.1. Surgery market revenue, by type (2017-2030)
• 7.4. Market Revenue, by Animal (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
  • 8.3.1. Surgery market revenue, by type (2017-2030)
• 8.4. Market Revenue, by Animal (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
  • 9.3.1. Surgery market revenue, by type (2017-2030)
• 9.4. Market Revenue, by Animal (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
  • 10.3.1. Surgery market revenue, by type (2017-2030)
• 10.4. Market Revenue, by Animal (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
  • 11.3.1. Surgery market revenue, by type (2017-2030)
• 11.4. Market Revenue, by Animal (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
  • 12.3.1. Surgery market revenue, by type (2017-2030)
• 12.4. Market Revenue, by Animal (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
  • 13.3.1. Surgery market revenue, by type (2017-2030)
• 13.4. Market Revenue, by Animal (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
  • 14.3.1. Surgery market revenue, by type (2017-2030)
• 14.4. Market Revenue, by Animal (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
  • 15.3.1. Surgery market revenue, by type (2017-2030)
• 15.4. Market Revenue, by Animal (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
  • 16.3.1. Surgery market revenue, by type (2017-2030)
• 16.4. Market Revenue, by Animal (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
  • 17.3.1. Surgery market revenue, by type (2017-2030)
• 17.4. Market Revenue, by Animal (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
  • 18.3.1. Surgery market revenue, by type (2017-2030)
• 18.4. Market Revenue, by Animal (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
  • 19.3.1. Surgery market revenue, by type (2017-2030)
• 19.4. Market Revenue, by Animal (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
  • 20.3.1. Surgery market revenue, by type (2017-2030)
• 20.4. Market Revenue, by Animal (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
  • 21.3.1. Surgery market revenue, by type (2017-2030)
• 21.4. Market Revenue, by Animal (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
  • 22.3.1. Surgery market revenue, by type (2017-2030)
• 22.4. Market Revenue, by Animal (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
  • 23.3.1. Surgery market revenue, by type (2017-2030)
• 23.4. Market Revenue, by Animal (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
  • 24.3.1. Surgery market revenue, by type (2017-2030)
• 24.4. Market Revenue, by Animal (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
  • 25.3.1. Surgery market revenue, by type (2017-2030)
• 25.4. Market Revenue, by Animal (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
  • 26.3.1. Surgery market revenue, by type (2017-2030)
• 26.4. Market Revenue, by Animal (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
  • 27.3.1. Surgery market revenue, by type (2017-2030)
• 27.4. Market Revenue, by Animal (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
  • 28.3.1. Surgery market revenue, by type (2017-2030)
• 28.4. Market Revenue, by Animal (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Charles River Laboratories International Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Merck KGaA
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Thermo Fisher Scientific Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. FUJIFILM Wako Pure Chemical Corporation
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. WuXi AppTec Co. Ltd.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Microcoat Biotechnologie GmbH
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Nelson Laboratories LLC
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Lonza Group Ltd.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Ellab A/S
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. GenScript Biotech Corporation
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports